Telix Pharmaceuticals Ltd. (AU:TLX) has released an update.
Telix Pharmaceuticals Limited reports a robust financial performance for Q1 2024, with a notable 75% increase in revenue to $175.0M and a substantial rise in gross profit by 84%, compared to the first quarter of the previous year. The company also turned an operating profit of $28.5M, a significant improvement from the $5.6M loss in the same quarter of 2023. With a steady closing cash balance of $122.7M, Telix underscores its commitment to regularly update its financial and business progress.
For further insights into AU:TLX stock, check out TipRanks’ Stock Analysis page.
